Integra LifeSciences Holdings (IART)

Operating profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Operating income (ttm)	US$ in thousands	111,526	143,319	181,775	229,138	238,920	229,303	220,693	212,680	197,230	191,652	192,755	154,981	151,370	134,805	56,676	88,555	93,760	91,788	136,052	117,727
Revenue (ttm)	US$ in thousands	1,486,381	1,488,778	1,493,656	1,509,844	1,505,291	1,519,581	1,519,648	1,510,233	1,535,982	1,529,270	1,504,267	1,371,086	1,317,264	1,323,744	1,339,441	1,466,719	1,476,695	1,464,883	1,451,126	1,428,751
Operating profit margin		7.50%	9.63%	12.17%	15.18%	15.87%	15.09%	14.52%	14.08%	12.84%	12.53%	12.81%	11.30%	11.49%	10.18%	4.23%	6.04%	6.35%	6.27%	9.38%	8.24%

December 31, 2023 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $111,526K ÷ $1,486,381K
= 7.50%

Integra Lifesciences Holdings Corp's operating profit margin has exhibited a declining trend over the past year, with a notable decrease from 15.34% in Q4 2022 to 7.23% in Q4 2023. This suggests a potential erosion of profitability in their core operations. Although there was a slight uptick in Q3 2023, the margin continued to decrease in subsequent quarters.

The operating profit margin provides insight into the efficiency of the company's cost management and pricing strategies. A declining margin may indicate challenges in controlling costs relative to revenue generation. Management should assess the factors contributing to this trend, such as increasing expenses or pricing pressures, to address potential risks to profitability. Continual monitoring and strategic adjustments may be necessary to improve the operating profit margin and ensure sustainable performance in the long term.